Controlled Substances Act & FDCA Violations Defense Overview
Allegations involving the Controlled Substances Act (CSA) or the Federal Food, Drug, and Cosmetic Act (FDCA) place individuals and organizations squarely in the government’s crosshairs. These are not routine regulatory matters—they are federal enforcement actions that can threaten careers, businesses, professional licenses, and personal freedom.
At Chapman, Dowling & Mallek, we represent physicians, pharmacists, healthcare executives, pharmaceutical companies, and regulated professionals facing some of the most aggressive investigations brought by the DEA, FDA, DOJ, and U.S. Attorney’s Offices nationwide. These cases demand far more than a general criminal defense approach. They require deep regulatory fluency, command of medical and scientific evidence, and the ability to dismantle complex federal enforcement theories—often before charges are ever filed.
What CSA & FDCA Defense Means in Practice
From a legal standpoint, Controlled Substances Act and FDCA defense is not a single tactic—it is a coordinated, precision-driven strategy designed to neutralize federal exposure at every stage of an investigation.
Controlled Substances Act (21 U.S.C. § 801 et seq.)
The CSA governs the manufacture, prescribing, dispensing, storage, and distribution of controlled substances. Federal prosecutors often allege that a provider or entity operated outside the “usual course of professional practice” or without a “legitimate medical purpose.”
Effective CSA defense focuses on:
- Clinical decision-making and medical necessity
- Prescribing intent and professional judgment
- DEA compliance and registration issues
- Recordkeeping and inventory controls
- Allegations of diversion or overprescribing
These cases frequently hinge on subjective interpretations of medical care—making early, strategic intervention critical.
Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 301 et seq.)
The FDCA empowers the FDA to regulate drug safety, manufacturing, labeling, and marketing. Criminal FDCA cases are often built on highly technical allegations that prosecutors oversimplify for leverage.
Common defense issues include:
- Misbranding and labeling disputes
- Alleged adulteration or manufacturing violations
- Off-label promotion allegations
- Failure to report adverse events
- Distribution or importation of unapproved products
At Chapman, Dowling & Mallek, we challenge these cases at their foundation—scientifically, procedurally, and constitutionally.
Common CSA & FDCA Allegations We Defend
Healthcare Professionals
- Alleged “pill mill” or improper prescribing cases
- Dispensing outside professional standards
- DEA audits and registration revocation proceedings
- Recordkeeping or reporting violations
- Diversion allegations involving staff or third parties
Pharmaceutical & Medical Product Companies
- Off-label marketing investigations
- Misbranding and adulteration claims
- Manufacturing and quality control enforcement
- Importation of unapproved or misclassified products
- Failure to register or comply with FDA requirements
Individuals
- Possession with intent to distribute
- Federal drug trafficking allegations
- Conspiracy charges tied to healthcare or pharmaceutical operations
Who Investigates These Cases
CSA and FDCA matters are rarely handled by a single agency. Investigations often involve coordinated federal task forces, including:
- Drug Enforcement Administration (DEA)
- FDA – Office of Criminal Investigations (OCI)
- Federal Bureau of Investigation (FBI)
- HHS Office of Inspector General (OIG)
- State medical, pharmacy, and professional licensing boards
- U.S. Attorney’s Offices
Parallel criminal, civil, and administrative proceedings are common—and missteps in one arena can severely damage another.
Potential Penalties and Exposure
CSA and FDCA violations carry some of the most severe penalties in federal law:
Criminal Consequences
- Lengthy federal prison sentences
- Massive fines and restitution
- Criminal forfeiture of assets
Civil & Administrative Sanctions
- Civil Monetary Penalties (CMPs)
- Exclusion from Medicare and Medicaid
- Loss or suspension of professional licenses
- DEA registration revocation
- Corporate Integrity Agreements (CIAs)
For professionals and executives, these penalties often represent the end of a career—not just a legal setback.
Overlapping Healthcare Fraud Exposure
CSA and FDCA cases frequently trigger broader federal fraud allegations, including:
- False Claims Act (FCA) investigations and qui tam lawsuits
- Anti-Kickback Statute enforcement
- Stark Law scrutiny
- Federal Healthcare Fraud (18 U.S.C. § 1347) charges
A disciplined defense strategy must account for every layer of exposure—not just the headline charge.
Why Clients Trust Chapman, Dowling & Mallek
CSA and FDCA cases are won—or quietly resolved—by law firms that understand how federal agencies actually build and pressure these cases.
Clients turn toChapman, Dowling & Mallek because we:
- Intervene early, often before charges are filed
- Understand the science, medicine, and regulatory mechanics behind the allegations
- Anticipate DOJ and agency enforcement strategies
- Protect professional licenses and federal program eligibility
- Pursue quiet resolutions whenever possible—and litigate aggressively when necessary
When federal regulators and prosecutors are scrutinizing your practice, products, or prescribing decisions, experience is not optional. It is decisive.
Government & Regulatory Sources:
- U.S. Drug Enforcement Administration (DEA) – Diversion Control Division:https://www.deadiversion.usdoj.gov/
- U.S. Food & Drug Administration (FDA) – Laws & Regulations:https://www.fda.gov/regulatory-information/laws-regulations-and-guidance
- U.S. Department of Justice (DOJ) – False Claims Act – Whistleblower Protection:https://www.justice.gov/civil/false-claims-act
- U.S. Department of Health & Human Services (HHS) – Office of Inspector General (OIG) – Fraud & Abuse Laws:https://oig.hhs.gov/compliance/physician-education/fraud-abuse-laws/